Abstract:Introduction Immunoglobulin light chain (AL) amyloidosis is a rare disease involving the clonal proliferation of bone-marrow-residing plasma cell and resulting in overproduction of serum immunoglobulin free light chains that affects multiple organs. There are several available effective treatments including autologous stem cell transplant, bortezomib, anti-CD38 antibodies, and immunomodulatory drugs. However, because of the atypical symptoms and signs of this disease, diagnostic delays are still the major challenge resulting in poor prognosis. In recent years, machine learning (ML) models have been used to assist in early diagnosis. Therefore, to address this clinical unmet need, we aim to build ML algorithms from clinical data and assess their performance in differentiating AL amyloidosis from similar conditions. Methods Monocenter medical records data were collected from 49 patients with AL amyloidosis and 198 non-AL amyloidosis patients on a ratio of 1:4 in Peking University People's Hospital between January 1, 2013, and December 31, 2021. The non-AL amyloidosis group were patients with diseases of similar symptoms including autoimmune liver disease, myocarditis, and hypertrophic cardiomyopathy. Variables for model development were selected from 30 demographic characteristics and clinical features from routine clinical examination based on the results of recursive feature elimination and hematologists' knowledge. We proposed a four-step approach to develop and evaluate the diagnostic models. In the first step, all patients were randomly allocated into a training set and a testing set with a ratio of 4:1. Second, we derived five separate ML models including logistic regression, support vector machine (SVM), extreme gradient boosting (XGBoost), light gradient boosting (LightGBM), and CatBoost algorithms to differentiate AL amyloidosis from other diseases with similar symptoms and validated the models using five-fold cross validation methods. Third, parameters of model with the highest areas under the receiver operating characteristic curves (AUROC) were updated in the full training set. Finally, the performances of the selected model were evaluated by AUROC, sensitivity, specificity and F1-score in the testing set. Results Twelve features including alanine aminotransferase, troponin, albumin, aspartate aminotransferase, activated partial thromboplastin time, albumin and globulin (A/G) ratio, direct bilirubin, platelet, fibrinogen, blood urea nitrogen, body weight and age were selected to construct ML models. The AUROC values for AL amyloidosis differential diagnosis were 0.55 with logistic regression, 0.63 with SVM, 0.84 with XGBoost, 0.89 with LightGBM, and 0.88 with CatBoost. The LightGBM model, which achieved the highest AUROC, also achieved the best performance with a sensitivity of 0.92, a specificity of 0.60, a F1-score of 0.73, a negative predictive value of 0.97, a positive predictive value of 0.60, and an accuracy of 0.82. Conclusion Our results show that the LightGBM model has the best performance to identify patients with AL amyloidosis from patients with similar symptoms. This novel ML-based diagnostic model has potential to assist in the earlier diagnosis of AL amyloidosis in clinical settings. Further studies are needed to confirm these findings in different study populations.

A machine learning model for early diagnosis of type 1 Gaucher disease using real-life data

Assessing the diagnostic utility of the Gaucher Earlier Diagnosis Consensus (GED-C) scoring system using real-world data

Early Prediction of Gestational Diabetes Mellitus in the Chinese Population Via Advanced Machine Learning

Machine Learning-Driven Biomarker Discovery for Skeletal Complications in Type 1 Gaucher Disease Patients

Prediction of gestational diabetes based on nationwide electronic health records

Early Prediction of High Risk Gestational Diabetes Mellitus <i>via</i> Machine Learning Models

Enhancing gestational diabetes mellitus risk assessment and treatment through GDMPredictor: a machine learning approach

Development and Validation of Machine Learning Models for Identifying Prediabetes and Diabetes in Normoglycemia

Applying Machine Learning to Support Early Diagnosis of Light-Chain Amyloidosis: A Combination of Knowledge-Based Approach with Data-Driven Approach

Enhancing Type 2 Diabetes Treatment Decisions With Interpretable Machine Learning Models for Predicting Hemoglobin A1c Changes: Machine Learning Model Development

Comparison of machine learning and conventional logistic regression-based prediction models for gestational diabetes in an ethnically diverse population; the Monash GDM Machine learning model

Development and economic assessment of machine learning models to predict glycosylated hemoglobin in type 2 diabetes

Early Prediction of Alzheimer's Disease and Related Dementias Using Real-World Electronic Health Records.

A Machine Learning Approach to Predicting Risk of Myelodysplastic Syndrome.

Using machine learning approaches to develop a fast and easy-to-perform diagnostic tool for patients with light chain amyloidosis: a retrospective real-world study

Prediction of Incident Diabetic Retinopathy in Adults With Type 1 Diabetes Using Machine Learning Approach: An Exploratory Study

A machine learning tool for identifying patients with newly diagnosed diabetes in primary care

Prediction of diabetic kidney disease with machine learning algorithms, upon the initial diagnosis of type 2 diabetes mellitus

Development of a machine learning algorithm for early detection of opioid use disorder

Development and external validation of a machine learning model to predict diabetic nephropathy in T1DM patients in the real-world

Comparison of Machine Learning Methods and Conventional Logistic Regressions for Predicting Gestational Diabetes Using Routine Clinical Data: A Retrospective Cohort Study